{"filing":{"accession_number":"0001104659-26-094391","cik":"0000842023","ticker":"TECH","company_name":"BIO-TECHNE Corp","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"tech-20260812x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/842023/000110465926094391/tech-20260812x8k.htm"},"events":[{"id":26996,"run_id":24562,"accession_number":"0001104659-26-094391","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Bio-Techne Corporation disclosed fourth quarter and full-year fiscal 2026 financial results on August 12, 2026, reporting quarterly revenue of $321.2 million and annual revenue of $1.2 billion, with GAAP EPS of $0.35 (quarterly) and $1.16 (annual), and adjusted EPS of $0.52 (quarterly) and $1.93 (annual), along with detailed segment performance and non-GAAP reconciliations.","company_name":"BIO-TECHNE Corp","ticker":"TECH","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28319,"accession_number":"0001104659-26-094391","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This Item 2.02 disclosure presents Bio-Techne's quarterly and annual financial results for the period ended June 30, 2026, with a press release attached as Exhibit 99.1. The filing reports fourth quarter and full-year fiscal 2026 results including revenue ($321.2M quarterly, $1.2B annual), GAAP EPS ($0.35 quarterly, $1.16 annual), and adjusted EPS ($0.52 quarterly, $1.93 annual), along with detailed segment performance and reconciliations of non-GAAP measures. This is a standard earnings release disclosure material to investors assessing the company's financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T10:31:58.041685+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28320,"accession_number":"0001104659-26-094391","item_number":"8.01","item_title":"Other Events","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 8.01 disclosure explicitly states \"A copy of the press release issued by Bio-Techne Corporation on August 12, 2026 announcing a cash dividend is attached hereto as Exhibit 99.2.\" However, the supplemental exhibit (EX-99.1) provided is the company's fourth quarter fiscal 2026 earnings release, which reports quarterly and full-year financial results including revenue of $321.2 million (Q4) and $1.2 billion (full year), GAAP EPS of $0.35 (Q4) and $1.16 (full year), and adjusted EPS of $0.52 (Q4) and $1.93 (full year). While the Item references a dividend announcement, the substantive disclosure furnished is the earnings release, which is the material event being disclosed under Item 8.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T10:31:58.041685+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28319,"accession_number":"0001104659-26-094391","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This Item 2.02 disclosure presents Bio-Techne's quarterly and annual financial results for the period ended June 30, 2026, with a press release attached as Exhibit 99.1. The filing reports fourth quarter and full-year fiscal 2026 results including revenue ($321.2M quarterly, $1.2B annual), GAAP EPS ($0.35 quarterly, $1.16 annual), and adjusted EPS ($0.52 quarterly, $1.93 annual), along with detailed segment performance and reconciliations of non-GAAP measures. This is a standard earnings release disclosure material to investors assessing the company's financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T10:31:58.041685+00:00","company_name":"BIO-TECHNE Corp","ticker":"TECH","filing_date":"2026-08-12"},{"id":28320,"accession_number":"0001104659-26-094391","item_number":"8.01","item_title":"Other Events","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 8.01 disclosure explicitly states \"A copy of the press release issued by Bio-Techne Corporation on August 12, 2026 announcing a cash dividend is attached hereto as Exhibit 99.2.\" However, the supplemental exhibit (EX-99.1) provided is the company's fourth quarter fiscal 2026 earnings release, which reports quarterly and full-year financial results including revenue of $321.2 million (Q4) and $1.2 billion (full year), GAAP EPS of $0.35 (Q4) and $1.16 (full year), and adjusted EPS of $0.52 (Q4) and $1.93 (full year). While the Item references a dividend announcement, the substantive disclosure furnished is the earnings release, which is the material event being disclosed under Item 8.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T10:31:58.041685+00:00","company_name":"BIO-TECHNE Corp","ticker":"TECH","filing_date":"2026-08-12"}]}